Pharming Group N.V. (PHGUF)
| Market Cap | 798.86M -19.4% |
| Revenue (ttm) | 366.48M +7.8% |
| Net Income | 9.30M |
| EPS | 0.01 |
| Shares Out | n/a |
| PE Ratio | 85.89 |
| Forward PE | 40.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 1.100 |
| Previous Close | 1.300 |
| Day's Range | 1.100 - 1.100 |
| 52-Week Range | 1.100 - 2.170 |
| Beta | 0.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev... [Read more]
Financial Performance
Financial StatementsNews
Pharming Launches Joenja In Japan For APDS
(RTTNews) - Pharming Group (PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for adult and children aged 4 years and older with activated PI3K delta syndrome, following its inclus...
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patient...
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V....
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V. (“Pharming” or the “Company”)...
Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) investors concerning the Company...
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) on behalf of investors concerning the Comp...
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)
Pharming Group shares fell 22% on July 30, 2026 after the Company reported a Q2 revenue decline and reduced its full-year 2026 outlook by roughly $30 million. Levi & Korsinsky is investigating potenti...
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
NEW YORK--(BUSINESS WIRE)--A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026 revenue of $90.2 million -- a 3% year-over-year decline against analyst c...
Pharming Group N.V.: Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Bo...
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Bost...
Pharming price target raised to $38 from $37 at Canaccord
Canaccord raised the firm’s price target on Pharming (PHAR) to $38 from $37 and keeps a Buy rating on the shares. The firm updated its model following mixed Q2 results…
Pharming Group Slides: Corporate presentation
Pharming Group has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)
Pharming Group's legacy product RUCONEST posted a 10% year-over-year sales decline in Q2 2026 -- and PHAR shares fell 22% the day it was reported. Levi & Korsinsky is investigating potential securitie...
Pharming (PHAR) Q2 2026 Earnings Call Transcript
Joenja revenue surged 40% as RUCONEST stabilized amid competitive pressure.
Pharming Group Q2 Earnings Call Highlights
Pharming Group NASDAQ: PHAR reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therap...
Pharming Group Earnings Call Transcript: Q2 2026
Revenue guidance for 2026 was lowered, but RUCONEST showed resilience and Joenja delivered 40% year-over-year growth. Operating discipline improved, with strong cash reserves and reduced expense guidance. Near-term catalysts include phase II leniolisib results and global Joenja expansion.
Pharming Group Earnings release: Q2 2026
Pharming Group released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Pharming Group Slides: Q2 2026
Pharming Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
For investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST revenue was US$72.3 million, a 10% decrease ...
Pharming Q2 Preview: Can Joenja Help Swing Back To Profit, Offsetting Ruconest Weakness?
(RTTNews) - Pharming Group N.V. (PHAR) announced that it will release preliminary results for the second quarter of fiscal 2026 along with business update on July 30, 2026. The company's management wi...
Earnings To Watch: Pharming Group (XAMS:PHARM) Q2 2026 -- GF Value Sees 36% Upside
Earnings To Watch: Pharming Group (XAMS:PHARM) Q2 2026 -- GF Value Sees 36% Upside
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the sec...
Pharming Group Transcript: Jefferies Global Healthcare Conference 2026
Leadership is focused on scaling rare disease capabilities, with RUCONEST providing stable cash flow and Joenja driving growth through new indications and global expansion. The pipeline is expanding with leniolisib in higher prevalence PIDs and the Abliva acquisition, targeting significant unmet needs.
Pharming Group Slides: FY 2026
Pharming Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.